Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN
#For patients
Written for adults considering a peptide as part of their health management.
Explainer
Semaglutide and menstrual changes
Semaglutide users report heavier periods and cycle shifts. Here is what safety data and clinical research say about GLP-1 agonists and menstruation.
Explainer
GLP-1 drugs in teens: what youth say
A qualitative study of 29 adolescents on GLP-1 and other weight-loss drugs finds families are positive about treatment but uncertain about when to stop.
Explainer
GLP-1 constipation: prevalence vs incidence
A 2026 study argues many GLP-1 users had constipation before starting treatment, inflating the headline rate.
Explainer
Mounjaro and Zepbound: same drug, different names. Here is why
Mounjaro and Zepbound are both Eli Lilly's tirzepatide. Same molecule, same doses, different brands sold for different indications. The marketing split is regulatory, not pharmacological.